NSCLC non-metastatic
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 27/04/2023)
PACIFIC-4 (AstraZeneca) (Stage IA3 or IB or IIA; EGFR-WT)
International Study of Durvalumab/Placebo Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515).
PACIFIC-4 (AstraZeneca) (Stage I or II; EGFR mutation)
International Study of Osimertinib Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515).
PACIFIC-8 (AstraZeneca) (Stage III; unresectable)
Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy.
BO44178 (Roche) (Stage IIIB/IIIC; unresectable; previously untreated)
A Study of RO7247669 Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer.
PACIFIC-4 (AstraZeneca) (Stage IA3 or IB or IIA; EGFR-WT)
International Study of Durvalumab/Placebo Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515).
PACIFIC-4 (AstraZeneca) (Stage I or II; EGFR mutation)
International Study of Osimertinib Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515).
PACIFIC-8 (AstraZeneca) (Stage III; unresectable)
Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy.
BO44178 (Roche) (Stage IIIB/IIIC; unresectable; previously untreated)
A Study of RO7247669 Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer.